Tendons – time to revisit inflammation

Jonathan D Rees,1 Matthew Stride,2 Alex Scott3

ABSTRACT
It is currently widely accepted among clinicians that chronic tendinopathy is caused by a degenerative process devoid of inflammation. Current treatment strategies are focused on physical treatments, peritendinous or intratendinous injections of blood or blood products and interruption of painful stimuli. Results have been at best, moderately good and at worst a failure. The evidence for non-inflammatory degenerative processes alone as the cause of tendinopathy is surprisingly weak. There is convincing evidence that the inflammatory response is a key component of chronic tendinopathy. Newer anti-inflammatory modalities may provide alternative potential opportunities in treating chronic tendinopathies and should be explored further.

INTRODUCTION: THE TENDINOSIS PARADIGM Pre1990s: the ‘tendinitis’ model
Prior to the 1990s pain arising from tendons was referred to as tendinitis, implying that inflammation was responsible for the pathological process. This view was both widely accepted and deeply ingrained in the medical literature.1 Treatment strategies at this time were largely anti-inflammatory in nature and relied heavily on non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.2 1

The move away from ‘tendinitis’: decade of the 1990s
Initially recognised by Puddu et al4 as long ago as the 1970s, in chronic tendinopathy there is an absence of acute inflammatory cells in the load-bearing regions of tendons.4 As histological data became more readily available this view became increasingly recognised. Several studies demonstrated collagen separation, thinning and disruption without an inflammatory cell infiltrate.5–7 There was also evidence from some animal studies that degenerative non-inflammatory tendon changes could be experimentally introduced over a brief (1 or 2 week) period.8 The pathology of chronic tendon disorders was correctly recognised as being very different from that of a characteristically inflammatory disease, such as rheumatoid arthritis (RA).

The move away from ‘tendinitis’ thinking was summed up concisely in a BMJ Editorial by Khan et al9 when practitioners and educators were urged “to accept the irresistible evidence that the term tendinitis must be abandoned to highlight a new perspective on tendon disorders”. At the time of the Editorial it was necessary for a strong message to be sent that chronic tendinopathy had a different aetiology to inflammatory conditions such as RA, and to emphasise that traditional strategies such as corticosteroid injection and NSAIDs do not adequately address the pathology. Although this remains an important message, we believe to regard all chronic tendinopathy as entirely non-inflammatory is an oversimplification to the point of being misleading.

Degeneration without inflammation: the paradigm of the 2000s
During the first decade of the 21st century ‘non-inflammatory’ or ‘degenerative’ theories have dominated thinking in tendinopathy. Various models have been proposed. First there are models that attempt to explain why tendons fail. The cumulative damage and vascular insufficiency models fall into the first group.2 Second, a group of models attempts to explain why tendons fail to repair themselves and includes the ‘failed healing response’10 and the continuum theories of tendinopathy.11 These theories and the degenerative ‘paradigm’ in general, have become extremely influential.

These ‘degenerative’ models have led to attempts to improve treatment and rehabilitation of the failing tendon. The common treatments that have been adopted during the 1990s can be broadly classified in four groups:

1. Physical exercises including eccentric exercises (EE) or other progressive loading regimes.
2. Treatments using blood and blood products that aim to improve tendon healing and remodelling.
3. Treatments that aim to reduce the pain associated with tendinopathy rather than heal the tendon itself (such as sclerosant or high-volume injections).
4. Extracorporeal shock wave therapy (ESWT). While there may be a degree of overlap between the treatment groups (eg, ESWT may influence pain processing) the point is none of these treatments are anti-inflammatory in nature.

Certainly much emphasis over the last 10 years has been placed on physical therapies. Eccentric exercises are shown to be effective in managing mid-portion Achilles tendinopathy.11 However, in subsequent studies the very high success rate found in this paper have not been repeated, highlighting the difficulties of EE in less-athletic populations.12 Furthermore, the success of this technique has not been satisfactorily demonstrated for other tendons.13–15 Other rehabilitation models that incorporate a variety of exercises, gradually increasing both load and velocity as the patient’s tolerance improves, have also been explored.16 17

A second area of treatment options are blood and blood products, including bone marrow-derived cells. Initial encouraging data from the equine field demonstrated the potential of stem cells to repair the hypoechogenic lesions seen on ultrasound (US).18 This method, requiring a bone marrow biopsy and in vitro cell expansion, is complicated and has not become routine in human clinical practice.
However, in humans, many attempts have been made to help ‘repair’ tendons by the use of more readily available agents particularly autologous blood and autologous blood products (principally platelet-rich plasma, PRP). The suggestion is that the cells and growth factors (such as vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in PRP) or other components of these preparations promote healing. While small uncontrolled studies have shown benefits from these treatments, evidence of the efficacy of these treatment strategies in good-quality in vivo studies is currently lacking. Indeed for PRP the level 1 evidence is that PRP is ineffective for mid-portion Achilles tendinopathy. Proponents of PRP argue that as there are numerous ways of preparing PRP and some methods may be more effective than others. Nevertheless, there is currently minimal scientific evidence that either PRP or autologous blood is effective when compared to placebo or no injection and further studies are going on.

The limitations of physical therapies and blood product injections in healing tendons have led to a different approach—with the aim of controlling pain through the disruption of the neural ingrowth that often accompanies neovessel formation in chronic tendinopathy. We describe these techniques as denervation procedures. Techniques in this emerging area include sclerosant therapy (eg, polidocanol and possibly dextrose); high-volume/tendon stripping injections; and some surgical techniques (such as paratendon stripping). These techniques are likely to exert their beneficial effect by interruption of neural ingrowth. As shock waves are toxic to peripheral nerves it is possible that ESWT may derive a beneficial effect, at least in part, from a direct effect on peripheral nerves.

Throughout the last decade the belief that chronic tendon conditions occur due to degeneration has become the prevailing paradigm. Unfortunately, with the possible exception of tendinosis, or indeed in the early stages of tendon overload, the aim of controlling pain through the disruption of the neural ingrowth that often accompanies neovessel formation in chronic tendinopathy. We describe these techniques as denervation procedures. Techniques in this emerging area include sclerosant therapy (eg, polidocanol and possibly dextrose), high-volume/tendon stripping injections and some surgical techniques (such as paratendon stripping). These techniques are likely to exert their beneficial effect by interruption of neural ingrowth. As shock waves are toxic to peripheral nerves it is possible that ESWT may derive a beneficial effect, at least in part, from a direct effect on peripheral nerves.

Throughout the last decade the belief that chronic tendon conditions occur due to degeneration has become the prevailing paradigm. Unfortunately, with the possible exception of mid-Achilles tendinopathy, the last decade has not provided us with therapies that are successful at ‘healing’ the failing tendon. However, is it certain that inflammation is not involved in the development or progression of tendinopathy? And if so are there other potential treatment options that have been overlooked?

CASE FOR INFLAMMATION IN CHRONIC TENDINOPATHY

Tendinosis myth

Although it was certainly progress to stop referring to all symptomatic tendons as ‘tendinitis’; does referring to all chronic tendons as ‘degenerative’ risks throwing the baby out with the bathwater? Ironically, it is now the ‘tendinosis’ paradigm that has itself become just as deeply ingrained in the medical literature as the original tendinitis concept. This has had two detrimental consequences. First, it oversimplifies our understanding of the pathological processes. Second it may lead us to ignore potentially effective treatments in chronic tendinopathy.

It is not suggested that acute inflammation is the dominant pathology in all phases of established tendinopathy. However, it is likely that elements of the inflammatory response play a role in the progression or continuation of tendon disruption. If so, could anti-inflammatory strategies be therapeutic in the chronically pathological tendon? Let us examine the case for the involvement of inflammation and inflammatory mediators in chronic tendinopathy.

‘Absence’ of inflammatory cells

The ‘tendinopathy paradigm’ was developed from several historical studies that had failed to show the presence of acute inflammatory cells (such as neutrophils and macrophages) in chronic tendinopathy, or indeed in the early stages of tendon overload. From this there was an inference that both acute and chronic tendinopathies are devoid of inflammation.

However, there have been major advances in immunohistochemistry and gene expression analysis subsequently. Several studies, in both humans and in animal models, have shown an inflammatory reaction both in established tendinopathy and in the early overload response. Schubert and coworkers have demonstrated the presence of macrophages and T and B lymphocytes in chronic Achilles tendinopathy using primary monoclonal antibodies (against CD68 for macrophages, CD3 for detection of T-lymphocytes and against CD20 for detection of B lymphocytes). The authors also studied asymptomatic spontaneously ruptured tendons and in contrast found large numbers of granulocytes (to be expected in the case of an acute traumatic event) but did not see significant numbers of macrophages, T- or B-lymphocytes.

Other studies in chronic tendinopathy have demonstrated increased levels of macrophage-derived interleukin-1 (IL-1), cyclo-oxygenase (COX)-1, COX-2, IL-6, iso-forms of transforming growth factor-β (TGF-β) and increased substance P. The classic Achilles overuse model (the Backman model) shows extensive inflammatory changes in the paratenon, with concomitant structural degeneration in the load-bearing tendon, after 3 weeks of acute overload.

Most studies of tendon pathology have histologically demonstrated an increase in tenocytes and that the tenocytes are larger than normal. Tenocytes are well known to proliferate and become more metabolically active in response to cytokines and growth factors that are part of the inflammatory response (eg, platelet-derived growth factor (PDGF), IGF-1 and TGF-β). Thus tenocyte hyperplasia and hypertrophy may provide indirect evidence of up-regulated inflammatory mediators.

It is possible that over time our understanding of tendinopathy will more closely resemble our current understanding of the pathological processes in osteoarthritis (OA). It is no longer believed that OA is caused simply by ageing and cartilage loading but indeed is an active process with infiltration of inflammatory cells (including CD4 T-cells) and natural killer cells. Again in OA mechanical overload (of the cartilage tissue) remains a key driver of pathology but the point is the evidence suggests it is mediated through elements of the inflammatory response. Furthermore, even if inflammation is not seen at a particular point in time, this in itself does not necessarily imply it is not inflammation that has caused tendinopathic changes in the first place. For example, in RA it is not disputed that inflammation causes damage. However, in treated RA (in clinical remission) damage (degeneration) is the key pathological finding which will be accompanied by a lack of an inflammatory infiltrate.

Neovessels

One of the most common findings on US of a chronically symptomatic tendon is power Doppler blood flow generally not seen in healthy tendons. This blood flow is referred to as neovascularisation. It is difficult to know if this neovascularisation represents genuine neoangiogenesis, however in histological studies of chronic tendinopathy angiogenesis is a common finding. There is a body of evidence to suggest that neural sprouting or neoinnervation accompanies neovessel formation, and that the neoinnervation may be a contributor or even responsible for the pain in chronic tendinopathy.

Two major molecular mechanisms of angiogenesis have been described—a hypoxia-dependent pathway and also a hypoxia-independent pathway. Pathological tendons are only one of
several pathologies that exhibit neovessel formation. These include inflammatory arthritis (such as RA, psoriatic arthritis and ankylosing spondylitis), OA, ischaemia, malignancy and diabetic retinopathy.

In inflammatory arthritis the neovascularity seen on US is generally regarded as confirming evidence of active inflammation. VEGF, produced in large quantities by macrophages, is thought responsible for the formation of both neovascularity and neoinnervation.

Nevertheless, there is a common view that neovessels are synonymous with ‘tendinosis’. Certainly many radiologists report neovessels as providing evidence of tendinosis. This is factually incorrect. Tendinosis is a histological term, which confirms that no inflammation is present; its presence cannot be confirmed or rejected following a US scan. It is also misleading as in order for neovessels to sprout it is very likely (in fact probably essential) that inflammatory mediators are involved at some stage in the process.

Power Doppler US assessment of, for example, an enthesal lesion or tendon body in a confirmed rheumatological inflammatory arthritis can look indistinguishable from that seen in a ‘degenerative’ tendinopathy (see figure 1).

Although the key drivers of neovessel formation in chronic tendinopathy remain the subject of ongoing research, there is strong evidence that the process of neovascularisation involves elements of the inflammatory response. For instance, when substance P is injected peritendinously, the vascularity of the tendon increases.

Biochemical influences on tendinopathy
There are several biochemical mediators that have been demonstrated to have an influence on the development and progression of chronic tendinopathy. These include the COX-1 and COX-2, matrix metalloproteinases (MMPs) and substance P.

The cyclooxygenase pathway is involved in classical inflammatory conditions (such as RA) and additionally processes with a more moderate degree of ongoing inflammation (such as osteoarthritis). It is known that peritendinous administration of prostaglandin E1 (PGE1) and elevated levels of PGE2 may lead to tendinopathic changes in tendon models.

Alterations in the concentrations and activity levels (both increased and decreased) of MMPs are well documented. A prolonged increase in the activity of MMP-1, MMP-3 and MMP-13 could lead to a loss of the biomechanical tendon properties; these MMPs have been linked to the degenerative changes seen in chronic tendinopathy. MMP-3 was found to be upregulated in the pathological rotator cuff, and correlated with the presence of retear—this MMP is positively regulated both by mechanical load and by substance P.

This process may, at least in part, be secondary to a failure of specific MMP regulation in response to repeated mechanical stimulus. Manipulation of MMPs, possibly through cytokine manipulation or inhibition, therefore provides potential to positively influence the role of MMPs in tendon degeneration and repair.

Substance P has been implicated as a proinflammatory mediator. Along with calcitonin gene-related peptide (CGRP) these nociceptive agents are significantly expressed in chronic tendinopathy. Substance P not only exerts a proliferative effect on tenocytes—it also increases their ratio of type III : type I collagen mRNA, which could contribute to the formation of smaller collagen fibres seen in tendinopathic tendons. Substance P also leads tenocytes to adopt a myofibroblast-like phenotype (ie, increased smooth muscle actin expression and increased contractile activity). Thus, the more proliferative and active phenotype of tenocytes observed in chronically painful tendon could result from local production of inflammatory mediators including substance P and potentially others.

So what can we conclude? There is a substantial, and growing, body of evidence indicating that ongoing tendon degeneration is an active process with involvement of many aspects of inflammation-mediated responses.
**Potential Therapeutic Agents in Chronic and Progressive Tendinopathy**

This paper has explored pathological mechanisms that are implicated in tendinopathy. By understanding better the pathology responsible for chronic progressive tendinopathy, this gives us the potential to rationally assess therapies that may be of benefit.

Chronic tendinopathy should be regarded as a process of degradation which appears to involve many aspects of the chronic injury-repair response, in common with other musculoskeletal rheumatological disorders. This degradation process, with characteristic features of neovessel formation, neoinnervation and synovitis, provides us with potential targets to modify the degradation process in a positive way.

This section of the paper describes the potential for ‘anti-inflammatory’ and other strategies to beneficially modulate both the chronic tendinopathy degradation and progressive tendinopathy process.

**Anti-inflammatory strategies and chronic tendinopathy**

Over the last 15 years the use of NSAIDs and corticosteroids has become less fashionable and more controversial in the management of chronic tendinopathy. But what does the evidence tell us? If inflammatory mediators are part of ongoing tendinopathy we should expect anti-inflammatory strategies to be at least partially effective in reducing tendon pain.

**Corticosteroids**

There is substantial evidence that corticosteroids can be effective in chronic tendinopathy at relieving pain, reducing swelling and improving function in the short term—although at the expense of greater risk of long-term recurrence.

This evidence extends to tendinopathy in many locations including patellar tendinopathy and lateral epicondylitis. Using an US-guided approach, Fredberg et al demonstrated benefit at 4 weeks, but the non-imaging approach adopted by DaCruz et al failed to show a benefit. A retrospective study of fluoroscopically guided corticosteroid injection into the potential space between the paratenon and tendon body found the procedure to be safe and improvements were seen in 40% at follow-up of 37 months.

A Cochrane review of corticosteroid injection use in shoulder pain has concluded that there is a benefit from subacromial corticosteroid injection in rotator cuff disease over placebo although again the evidence generally extends only to the short term.

The issues relating to corticosteroid injection are therefore less than they do not work, but more that the benefits are generally short term, and that there is the potential for weakening the structural integrity of tendons in the long-term.

The exact mechanism by which corticosteroids have an effect on tendon pain is unclear. Corticosteroids are to some extent indirect vasoconstrictors, through suppression of production of the vasodilators prostacyclin and nitric oxide (NO) as well as exhibiting anti-inflammatory effects. They may also influence the perception of pain by altering local nociception.

The challenge is to determine exactly how corticosteroids exert their beneficial effect on nociceptive and inflammatory pathways, and to develop more refined future therapies without the long-term increased risk of symptom recurrence.

**Non-steroidal anti-inflammatory drugs**

NSAIDs have a more specific anti-inflammatory role when compared with that of corticosteroids and remain in common clinical use. Most are non-selective inhibitors of COX which catalyses the formation of prostaglandins and thromboxane from arachidonic acid.

In a review of NSAIDs in tendinopathy, Almekinders and Temple found pain relief in five of nine prospective and placebo-controlled studies. A more recent review of NSAIDs including 17 placebo-controlled studies confirmed NSAIDs were effective in relieving pain in the short term (7–14 days) in 14 of the 17 studies. A Cochrane review of interventions for treating acute and chronic Achilles tendinitis found weak evidence of a moderate effect of NSAIDs, both oral and topical, on acute tendon pain.

The beneficial effects of NSAIDs on tendon pain may be related to their anti-inflammatory properties or possibly via analgesia effect modulation of nociception. Unlike acetaminophen (paracetamol), which is not considered an NSAID and whose nociceptive effects are mainly mediated by blocking COX activity in the central nervous system (CNS), most NSAIDs penetrate poorly into the CNS, and indeed topical NSAIDs would not be expected to reach levels within the CNS capable of exerting a clinically meaningful analgesic effect.

Concerns remain in relation to the use of NSAIDs both in terms of systemic effects and the potential to affect tendon healing. In relation to tendon healing, in animal studies conflicting results have been noted with either an increase in tensile strength or a reduction in breaking point being reported.

The key point here is that the apparent effect of NSAIDs on tendon pain in multiple studies suggests a potential role of inflammation in chronic tendinopathy.

**Antitumor necrosis factor α agents**

Tumour necrosis factor α (TNF-α) is a pro-inflammatory cytokine that is capable of inducing a profound inflammatory response by upregulating pro-inflammatory agents including IL-1, IL6, MMP1 and MMP3, VEGF and PGE2. Upregulation of TNF-α is associated with apoptosis; apoptosis being a feature of chronic tendinopathy.

Inhibition of TNF-α, by synthetic monoclonal biological agents (either as a neutralising antibody or a soluble TNF receptor) is highly effective in treating inflammation associated with active RA and sero-negative spondylarthritides including ankylosing spondylitis. These agents have powerful anti-inflammatory actions and have been shown to regulate IL6, IL8, MCP-1 and VEGF, reduce angiogenesis and reduce blood levels of MMP-1 and MMP-3. These monoclonal antibodies are potent inhibitors of TNF.

The use of weakly (less potent) anti-TNF agents in acute tendinopathy has been advocated by others. Just one study to date has examined the use of the potent anti-TNF-α in chronic tendinopathy. Peritendinous use of adalimumab (a fully humanised anti-TNF receptor antagonist) has been used in chronic Achilles tendinopathy. In this small study, it was found that adalimumab injections had a significant effect on pain sensitisation at rest in chronic Achilles tendinopathy and reduced blood flow at 12 weeks.

Use of these agents in a systemic manner is not straightforward and has not yet been studied. They are expensive (approximately £10 000 per inflammatory arthritis patient treated per calendar year). Additionally, they are powerful immunosuppressants with re-activation of latent TB a particular and serious concern.

Nevertheless, the pilot study demonstrates that targeting TNF-α or other inflammatory cytokines could be a valid approach in chronic progressive tendinopathy. More studies are required.
Matrix metalloproteinase activity, inhibition and regulation

The extra cellular matrix (ECM) in the main body of the tendon consists primarily of type I collagen, while the predominant proteoglycan component is the small leucine-rich proteoglycan decorin, and the principal large aggregating proteoglycan is versican.65

Proteoglycan processing is a normal part of tendon physiology. Over their lifespan tenocytes are active and involved in both the production of tendon matrix proteins (including MMPs) and matrix degrading enzymes (tissue inhibitors of metalloproteinases or TIMPs).44 45 Both MMPs (through their broad proteolytic capability) and TIMPs are involved in the physiological remodelling of the ECM.46 66

Thus in health the matrix is in a constant state of flux between synthesis and degradation and regulated by this activity of MMPs and TIMPs. However imbalances of MMPs or TIMPs may produce collagen disturbances in tendons.67 Jones et al have demonstrated reduced expression of ADAMTS-5 levels in tendinopathy and, via mRNA profiling of genes from MMP ADAMTS and TIMP families, that normal, chronically painful and ruptured tendons have distinct proteolytic mRNA profiles.66

This is further evidence to support the view that chronic tendinopathy is not just a passive process but is an active process of degradation. This raises the possibility that manipulation of MMP pathways could beneficially alter pain and/or tendon matrix degradation. The metalloproteinase ADAMTS-5, for example, is already considered a potential target for the treatment of tendon degeneration and neovascularisation.43

Substance P, glutamate and pain inhibition as a potential therapy in tendinopathy

Substance P has long been recognised as an important molecule in nociception and pain signalling. Substance P has been found in increased levels in chronic tendon pathology.34 It is increased following overload of the rabbit Achilles tendon 69 and also accelerates hypercellularity and angiogenesis.43

Increased levels of glutamate, originally thought to be confined to the CNS have been documented to be present in microdialysis of symptomatic Achilles tendon tissue.70 Furthermore, elevated levels of the glutamate receptor, N-methyl-D-aspartate receptor type 1 (NMDAR1) have also been documented in chronic tendinopathy.71 In this study of patients with symptomatic patellar tendinopathy there was a 9-fold increase of NMDAR1 and a 10-fold increase of glutamate compared with controls.

It was suggested by the authors of this paper that the neuronal coexistence of elevated NMDAR1 and glutamate suggests a regulatory role in intensified pain signalling. Coexistence is the presence of two or more transmitters in a single neuron.72 This leads to the possibility that inhibition of substance P and/or glutamate could be beneficial not only in reducing pain but also in reducing ongoing tendon degradation.

Neovessels: can we inhibit their formation?

If the process of neovascularisation leads to painful neoinnervation then treatments that stop or hinder the neovascularisation may be successful at reducing the pain in chronic tendinopathy. Current treatments (eg, high-volume injections) treat neovessels once they have occurred, but there is a tendency for the neovessels to reform postprocedure. Potentially, agents that inhibit VEGF and other agents involved in neovessel formation may inhibit their formation and propagation.

Nerve growth factor (NGF) is essential for the maintenance of both sensory and sympathetic neurones and refers to a single protein. Nerve growth factor belongs to a family of factors also known as neurotrophins and include brain-derived neurotrophic factor (BDNF). Both NGF and BDNF together with the neurotrophin receptor p75 have been detected in Achilles tendon tenocytes.73 NGF is believed to play a role in the development of neuropathic pain. NGF inhibitors, including the monoclonal antibody to NGF tanezumab, are currently undergoing phase 2 clinical trials and, if the trials are successful, could be an option in chronic tendon pain with neoinnervation.

CONCLUSION

Tendinopathy remains both an extremely common condition and a condition with few truly effective treatments. Over the last decade various models have been proposed to explain the pathological process underpinning tendinopathy. These models have suggested a primarily degenerative pathological process and some have clearly stated that the process of tendon overuse pathology is non-inflammatory in nature. Indeed this has become a paradigm for thinking about tendinopathy.

This paper has highlighted the limitations of this current view. More modern research tools have confirmed the presence of inflammatory cells including macrophages and lymphocytes in chronic tendinopathy, particularly in closely associated tissue (eg, bursa or paratenon). In addition to inflammatory cells, there is evidence that numerous other mediators including substance P, MMPs, VEGF and COX which play a role in chronic tendon pathology.

This does not mean that the pathology of chronic tendinopathy mirrors that of inflammatory arthritis. We do not advocate going back to the ‘tendinitis’ model, and there is no doubt that a shift away from primarily anti-inflammatory strategies has had great benefit for tendinopathy treatments, by placing the emphasis on active rehabilitation to attempt to regain function and potentially lead to enhanced tissue remodelling.

Mechanical overload is still likely to be the dominant factor involved in initiation of an inflammatory response—the point is that at least some of the damage caused by this overload is mediated through a process that involves elements of the inflammatory process.

An appreciation of the basic science involved in tendinopathy gives us a whole new potential armamentarium of treatments that we can use. It is hoped that tendon research will be driven by a greater awareness of the potential for managing and targeting the inflammatory response.

What this paper add to this subject?

- Chronic tendinopathy incorporates elements of the inflammatory response.
- The term tendinosis should not be used to describe the radiological appearances of neovascularisation.
- More emphasis should be placed on the potential for anti-inflammatory strategies in chronic tendinopathy.

Competing interests None.

Contributors JR and MS have contributed to the original concept, research, writing of article, editing and approval of the final draft. AS has given suggestions on original concept, editing, additional ideas and approval of the final draft.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES


1. The following terms best describe tendinosis.
   A. A painful tendon
   B. A tendon which demonstrates grey scale changes on ultrasound (US) such as thickening and hypoechogenecity.
   C. It is a histological term reserved for the histological appearance of a tendon.
   D. Can be correctly diagnosed on MRI scan.
   E. Implies inflammation is present.

2. Inflammation is most appropriately described by:
   A. A “multi-mediated phenomenon, of a pattern type in which all mediators would come and go at the appropriate moment... increasing vascular permeability, attracting leukocytes, producing pain, local edema and necrosis”.
   B. Always characterized by the presence of all five cardinal signs: heat, swelling, redness, pain and loss of function.
   C. Never occurring in tendons or their surrounding tissues.
   D. The focus of treatment for a patient with chronic tendinopathy.
   E. Always being necessary for tissue healing.

Correct answer: A. The biochemical definition of inflammation (Rocha e Silva, 1974) is widely accepted today. Inflammation is not a single phenomenon. It is a rather wide-reaching concept, which includes a multitude of events which may occur together or independently to varying extents. Thus, elements of an inflammatory response may be present without all five cardinal signs. Following either acute injuries (eg, laceration and contusion) or acute bouts of mechanical load, both the tendon and its surrounding tissues may experience bouts of inflammation. Over time, this may lead to the loss of tendon structure, scarring, adhesions, metaplasia etc. The focus of treatment for a chronic tendinopathy should be load management and graduated rehabilitation with attention to optimal biomechanics. Tissue healing can occur through intrinsic cellular activity, in the absence of inflammatory cells or cardinal signs.

3. Regarding neo-vasculosity, which of the following statements is most appropriate?
   A. The presence of neo-vessels confirms a diagnosis of tendinosis.
   B. The extent of neo-vascularity correlates well with the clinical severity of tendinopathy.
   C. The appearances of a tendon in clinically recognized tendinopathy. Vascular endothelial growth factor (VEGF) is thought to be responsible for the formation of both neo-vasculosity and neo-innervation.

4. Regarding denervation techniques performed on tendons:
   A. They are techniques performed on the tendon directly.
   B. The main aim is to improve tendon healing.
   C. The effect is believed to be through the interruption of neural stimulation.
   D. These techniques are usually performed surgically.

5. Which of the following statements regarding substance-P is incorrect?
   A. It is a neuropeptide.
   B. Along with calcitonin gene-related peptide (CGRP), it is significantly expressed in chronic tendinopathy.
   C. It acts as a proinflammatory mediator.
   D. It increases the rate of type IV: type I collagen mRNA, which could contribute to the formation of smaller collagen fibres seen in tendinopathic tendons.
   E. It coexists with the neurotransmitter glutamate in primary afferents that respond to painful stimuli.

Answer D. Increases the ratio of type III: type I collagen. All other statements are correct.
Tendons – time to revisit inflammation

Jonathan D Rees, Matthew Stride and Alex Scott

Br J Sports Med published online March 9, 2013
doi: 10.1136/bjsports-2012-091957

Updated information and services can be found at:
http://bjsm.bmj.com/content/early/2013/03/08/bjsports-2012-091957.full.html

These include:

References
This article cites 69 articles, 17 of which can be accessed free at:
http://bjsm.bmj.com/content/early/2013/03/08/bjsports-2012-091957.full.html#ref-list-1

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. See:
http://creativecommons.org/licenses/by-nc/3.0/ and
http://creativecommons.org/licenses/by-nc/3.0/legalcode

Published online March 9, 2013 in advance of the print journal.

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Articles on similar topics can be found in the following collections

Open access (121 articles)
Drugs: musculoskeletal and joint diseases (82 articles)

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Notes

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/